{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:10:08Z","timestamp":1783019408393,"version":"3.54.6"},"reference-count":21,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"5","license":[{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"vor","delay-in-days":388,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction:<\/jats:title>\n                  <jats:p>Intramuscular antipsychotics are commonly used to manage agitated patients. In 2005, Eli Lilly placed a warning on olanzapine's prescribing information following post-marketing reports of fatal drug reactions when intramuscular olanzapine was used in the setting of benzodiazepines. Data is lacking examining this drug combination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>A medication use evaluation was conducted at a county psychiatric hospital surveying the usage of concomitant intramuscular olanzapine and lorazepam from October 1, 2016, to July 20, 2017. A literature search was conducted to review available evidence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Ninety-one instances of the drug combination were discovered, with no serious adverse events following administration. Of these 91 patients, 41 received both medications within 60 minutes of each other. No instances of hypotension, bradycardia, bradypnea, or oxygen desaturation occurred following administration. The literature review yielded 1 randomized, placebo-controlled clinical trial, 3 retrospective chart reviews, and several case studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion:<\/jats:title>\n                  <jats:p>Data detailing a causal relationship between olanzapine\/benzodiazepine combinations and serious adverse effects is lacking. Available evidence does not consistently support a strong cause and effect relationship. The results of this medication use evaluation are not consistent with the Food and Drug Administration warning. Further controlled research is needed to help define the actual risk of using concomitant intramuscular olanzapine and benzodiazepines.<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2018.09.208","type":"journal-article","created":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T13:33:42Z","timestamp":1536068022000},"page":"208-213","source":"Crossref","is-referenced-by-count":25,"title":["Coadministration of intramuscular olanzapine and benzodiazepines in agitated patients with mental illness"],"prefix":"10.9740","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3140-414X","authenticated-orcid":false,"given":"Andrew M.","family":"Williams","sequence":"first","affiliation":[{"name":"(Corresponding author) Clinical Pharmacist, Riverside University Health System, Riverside, California; Adjunct Assistant Professor of Pharmacy Practice, University of Southern California School of Pharmacy, Los Angeles, California; Adjunct Assistant Clinical Professor, University of the Pacific Thomas J. Long School of Pharmacy, Stockton, California; Assistant Clinical Professor of Pharmacy Pract"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","reference":[{"issue":"12","key":"2020060307283682200_i2168-9709-8-5-208-b01","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/j.1553-2712.2008.00282.x","article-title":"A survey of workplace violence across 65 U.S. emergency departments","volume":"15","author":"Kansagra","year":"2008","journal-title":"Acad Emerg Med"},{"issue":"2","key":"2020060307283682200_i2168-9709-8-5-208-b02","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.pop.2016.01.009","article-title":"Psychiatric emergencies","volume":"43","author":"Wheat","year":"2016","journal-title":"Prim Care"},{"issue":"6","key":"2020060307283682200_i2168-9709-8-5-208-b03","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.ajem.2005.02.050","article-title":"Emergency management of agitation in schizophrenia","volume":"23","author":"Marco","year":"2005","journal-title":"Am J Emerg Med"},{"issue":"4","key":"2020060307283682200_i2168-9709-8-5-208-b04","first-page":"327","article-title":"Treatment of acute agitation in psychotic disorders","volume":"26","author":"Mohr","year":"2005","journal-title":"Neuro Endocrinol Lett"},{"issue":"1","key":"2020060307283682200_i2168-9709-8-5-208-b05","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5811\/westjem.2011.9.6866","article-title":"The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project BETA Psychopharmacology Workgroup","volume":"13","author":"Wilson","year":"2012","journal-title":"West J Emerg Med"},{"issue":"6","key":"2020060307283682200_i2168-9709-8-5-208-b06","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.jemermed.2014.01.017","article-title":"Despite expert recommendations, second-generation antipsychotics are not often prescribed in the emergency department","volume":"46","author":"Wilson","year":"2014","journal-title":"J Emerg Med"},{"issue":"6","key":"2020060307283682200_i2168-9709-8-5-208-b07","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/PRA.0000000000000186","article-title":"Dopheide J. Antipsychotic selection for acute agitation and time to repeat use in a psychiatric emergency department","volume":"22","author":"Gomez","year":"2016","journal-title":"J Psychiatr Pract"},{"issue":"12","key":"2020060307283682200_i2168-9709-8-5-208-b08","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.4088\/JCP.v69n1204","article-title":"A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation","volume":"69","author":"Satterthwaite","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"2020060307283682200_i2168-9709-8-5-208-b09","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003729.pub2","article-title":"Olanzapine IM or velotab for acutely disturbed\/agitated people with suspected serious mental illnesses","author":"Belgamwar","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2020060307283682200_i2168-9709-8-5-208-b10","article-title":"Some Abilify formulations to discontinue in 2015","author":"Han","year":"2015","journal-title":"MPR [Internet]"},{"issue":"3","key":"2020060307283682200_i2168-9709-8-5-208-b11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.annemergmed.2016.07.033","article-title":"Midazolam-droperidol, droperidol, or olanzapine for acute agitation: a randomized clinical trial","volume":"69","author":"Taylor","year":"2017","journal-title":"Ann Emerg Med"},{"issue":"4","key":"2020060307283682200_i2168-9709-8-5-208-b12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0735-6757(97)90119-4","article-title":"Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study","volume":"15","author":"Battaglia","year":"1997","journal-title":"Am J Emerg Med"},{"issue":"04","key":"2020060307283682200_i2168-9709-8-5-208-b13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4088\/JCP.08m04411gry","article-title":"Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation","volume":"71","author":"Marder","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"2020060307283682200_i2168-9709-8-5-208-b14","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.2146\/ajhp070460","article-title":"Optimizing patient safety by preventing combined use of intramuscular olanzapine and parenteral benzodiazepines","volume":"65","author":"Naso","year":"2008","journal-title":"Am J Health Syst Pharm"},{"issue":"5","key":"2020060307283682200_i2168-9709-8-5-208-b15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jemermed.2010.04.012","article-title":"Potential complications of combining intramuscular olanzapine with benzodiazepines in emergency department patients","volume":"43","author":"Wilson","year":"2012","journal-title":"J Emerg Med"},{"issue":"5","key":"2020060307283682200_i2168-9709-8-5-208-b16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1013\/j.jemermed.2011.01.024","article-title":"A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation","volume":"43","author":"Wilson","year":"2012","journal-title":"J Emerg Med"},{"key":"2020060307283682200_i2168-9709-8-5-208-b17","article-title":"Zyprexa (olanzapine) package insert","year":"2017","journal-title":"Indianapolis: Lilly Research Laboratories"},{"issue":"8","key":"2020060307283682200_i2168-9709-8-5-208-b18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1176\/pn.40.8.00400001","article-title":"Zyprexa IM caution issued in some countries but not U.S","volume":"40","author":"Moran","year":"2005","journal-title":"Psychiatr News"},{"issue":"12","key":"2020060307283682200_i2168-9709-8-5-208-b19","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.4088\/JCP.v66n1219c","article-title":"Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam","volume":"66","author":"Zacher","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"2020060307283682200_i2168-9709-8-5-208-b20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1744-859X-6-11","article-title":"Intramuscular olanzapine \u2013 a UK case series of early cases","volume":"6","author":"Bushe","year":"2007","journal-title":"Ann Gen Psychiatry"},{"issue":"1","key":"2020060307283682200_i2168-9709-8-5-208-b21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.annemergmed.2012.07.118","article-title":"Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial","volume":"61","author":"Chan","year":"2013","journal-title":"Ann Emerg Med"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/8\/5\/208\/2096342\/mhc_2018_09_208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/8\/5\/208\/2096342\/mhc_2018_09_208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:22:39Z","timestamp":1731687759000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/8\/5\/article-p208.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2018.09.208","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}